IE44055B1 - Phthalanes - Google Patents

Phthalanes

Info

Publication number
IE44055B1
IE44055B1 IE5/77A IE577A IE44055B1 IE 44055 B1 IE44055 B1 IE 44055B1 IE 5/77 A IE5/77 A IE 5/77A IE 577 A IE577 A IE 577A IE 44055 B1 IE44055 B1 IE 44055B1
Authority
IE
Ireland
Prior art keywords
formula
compound
dimethylaminopropyl
acid addition
phthalancarbonitrile
Prior art date
Application number
IE5/77A
Other languages
English (en)
Other versions
IE44055L (en
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE44055(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of IE44055L publication Critical patent/IE44055L/xx
Publication of IE44055B1 publication Critical patent/IE44055B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IE5/77A 1976-01-14 1977-01-04 Phthalanes IE44055B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (2)

Publication Number Publication Date
IE44055L IE44055L (en) 1977-07-14
IE44055B1 true IE44055B1 (en) 1981-07-29

Family

ID=9722860

Family Applications (1)

Application Number Title Priority Date Filing Date
IE5/77A IE44055B1 (en) 1976-01-14 1977-01-04 Phthalanes

Country Status (19)

Country Link
US (1) US4136193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS52105162A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT359488B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU509445B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE850401A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1094087A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (3) CH626886A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2657013C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK143275C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES454980A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI63754C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2338271A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1526331A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE44055B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL192451C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO147243C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ183001A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE429551B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA7757B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
AU737610B2 (en) 1997-07-08 2001-08-23 H. Lundbeck A/S Method for the preparation of citalopram
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
EP1042310B1 (en) 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
HU228576B1 (en) 1998-10-20 2013-04-29 Lundbeck & Co As H Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
KR20010081071A (ko) 1998-12-08 2001-08-25 피터슨 존 메이달 벤조푸란 유도체, 그것들의 제조 및 사용
AU764161B2 (en) 1998-12-23 2003-08-14 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
HU227473B1 (en) * 1999-04-14 2011-07-28 Lundbeck & Co As H Method for preparation of citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
HUP0200169A3 (en) 1999-10-25 2002-11-28 Lundbeck & Co As H Method for the preparation of citalopram
EP1228056B1 (en) * 1999-10-25 2004-09-22 H. Lundbeck A/S Method for the preparation of citalopram
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
JP2003519136A (ja) * 1999-12-28 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
MXPA02006504A (es) * 1999-12-30 2002-12-09 Lundbeck & Co As H Metodo para la preparacion de citalopram.
IL150561A0 (en) * 2000-01-14 2003-02-12 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
SK14522002A3 (sk) * 2000-03-13 2003-03-04 H. Lundbeck A/S Spôsob prípravy citalopramu a citalopram pripravený týmto spôsobom
CZ20023384A3 (cs) * 2000-03-13 2003-01-15 H. Lundbeck A/S Způsob výroby citalopramu a meziprodukt
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
JP2003527386A (ja) 2000-03-14 2003-09-16 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
CN1418206A (zh) * 2000-03-16 2003-05-14 H·隆德贝克有限公司 5－氰基－1－(4－氟苯基)－1,3－二氢异苯并呋喃的制备方法
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
IL148525A0 (en) * 2000-07-06 2002-09-12 Lundbeck & Co As H Method for the preparation of citalopram
SK2022003A3 (en) * 2000-07-21 2003-06-03 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
IL144816A (en) * 2000-08-18 2005-09-25 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
CN1282648C (zh) * 2000-12-22 2006-11-01 H·隆德贝克有限公司 制备纯西酞普兰的方法
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
EP1181272B1 (en) * 2000-12-28 2002-08-28 H. Lundbeck A/S Process for the preparation of pure citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
CA2435925A1 (en) * 2001-01-30 2002-08-08 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
CN1492861A (zh) * 2001-02-22 2004-04-28 纳特科药品有限公司 西酞普兰的制备方法
GB0105627D0 (en) 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
CA2439856A1 (en) * 2001-03-09 2002-09-19 Swargam Sathyanarayana Process for the preparation of citalopram
HRP20030744A2 (en) * 2001-05-01 2005-06-30 H. Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
ZA200309684B (en) 2001-07-31 2004-12-22 Lundbeck & Co As H Crystalline composition containing escitalopram.
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
CN103288815A (zh) * 2001-10-12 2013-09-11 阿泽范药品公司 β-内酰胺后叶加压素V1a拮抗剂
IN192863B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
GB2387596B (en) * 2002-02-27 2004-02-11 Matrix Lab Ltd Process
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
WO2003080558A1 (fr) * 2002-03-27 2003-10-02 Bando Chemical Industries, Ltd. Nouveau 1,3,5-tris(arylamino)benzène
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
PE20040991A1 (es) * 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
WO2004016602A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
RS51092B (sr) * 2002-12-23 2010-10-31 H. Lundbeck A/S. Escitalopram bromhidrat i postupak za njegovo pripremanje
AU2003242990A1 (en) * 2003-01-17 2004-08-13 Pulla Reddy Muddasani Processes for the preparation of escitalopram and its precursor
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
US7019153B2 (en) * 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
PT1668014E (pt) * 2003-09-17 2009-03-17 Janssen Pharmaceutica Nv Compostos heterocíclicos fundidos como moduladores do receptor de serotonina
SI1506963T1 (en) * 2003-10-28 2005-10-31 Adorkem Technology Spa Method for the preparation of citalopram
AU2003278409A1 (en) * 2003-10-28 2005-05-19 Krishnaji Upadhye Bhargav Improved process for the manufacture of citalopram hydrobromide
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
EP1723133A1 (en) * 2004-02-16 2006-11-22 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
EP1797060A2 (en) 2004-08-23 2007-06-20 Sun Pharmaceutical Industries Limited "process for preparation of citalopram and enantiomers"
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
AU2006239920A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
TWI347942B (en) 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
JP5328349B2 (ja) 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1951726A2 (en) * 2005-11-14 2008-08-06 H.Lundbeck A/S Method for the preparation of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PA8720801A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP1988086B2 (en) 2007-04-23 2014-11-26 Synthon B.V. Process for resolving citalopram via its (S)-enriched citalopram tartrate compound.
CA2685424A1 (en) * 2007-05-18 2008-11-27 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101859409B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
KR102725123B1 (ko) 2014-03-28 2024-11-04 아제반 파마슈티칼스, 인코퍼레이티드 신경변성 질환을 치료하기 조성물 및 방법
IL319248A (en) * 2016-03-10 2025-04-01 Janssen Pharmaceutica Nv Methods for treating depression using orexin-2 receptor antagonists
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
CN114375191A (zh) 2019-07-19 2022-04-19 比奥克斯塞尔医疗股份有限公司 非镇静的右美托咪定治疗方案
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1965-03-18

Also Published As

Publication number Publication date
FR2338271A1 (fr) 1977-08-12
DK143275B (da) 1981-08-03
NO147243B (no) 1982-11-22
CH626886A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-12-15
BE850401A (fr) 1977-07-14
GB1526331A (en) 1978-09-27
NL7700244A (nl) 1977-07-18
CA1094087A (en) 1981-01-20
SE7614201L (sv) 1977-07-15
NL192451C (nl) 1997-08-04
FI63754B (fi) 1983-04-29
DK13177A (da) 1977-07-15
AU509445B2 (en) 1980-05-15
ATA947276A (de) 1980-04-15
NL970031I2 (nl) 1997-10-01
NO770109L (no) 1977-07-15
CH632258A5 (de) 1982-09-30
FR2338271B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-11-05
AT359488B (de) 1980-11-10
ZA7757B (en) 1977-11-30
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
US4136193A (en) 1979-01-23
JPS6135986B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-08-15
NO1996001I1 (no) 1996-01-05
SE429551B (sv) 1983-09-12
AU2107377A (en) 1978-07-13
DK143275C (da) 1982-01-18
FI63754C (fi) 1983-08-10
FI770073A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-07-15
JPS52105162A (en) 1977-09-03
NZ183001A (en) 1978-06-02
IE44055L (en) 1977-07-14
DE2657013C2 (de) 1985-11-14
ES454980A1 (es) 1978-04-01
NO147243C (no) 1983-03-02
DE2657013A1 (de) 1977-07-28
CH632259A5 (de) 1982-09-30

Similar Documents

Publication Publication Date Title
US4136193A (en) Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans
JP2637737B2 (ja) 新規な薬剤
IE65734B1 (en) New enantiomers and their isolation
HU176709B (en) Process for preparing new trisubstituted 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine derivatives
US4086350A (en) Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
CA1055945A (en) Pharmaceutical compositions and method of producing antipsychotic activity without extrapyramidal symptoms
HU184359B (en) Process for preparing substituted acyl-carbamides
US4540691A (en) Dopamine agonists and use thereof
US4654352A (en) Method for treating diarrhea with benzothiophene derivatives
JPS61249966A (ja) ベンゾアゼピン誘導体
JPS6040422B2 (ja) 置換１‐アルキルチオフエニル―２，３，４，５―テトラヒドロ―１ｈ―３―ベンズアゼピン化合物
CA1102807A (en) Piperidylidene derivatives of benzo-fused xanthenes, thioxanthenes and dibenzoxepins
JPH089580B2 (ja) アミノアルコ−ル、その製造法およびその用途
US4616017A (en) Aminohydroxypropoxy substituted aryl compounds
JP3172543B2 (ja) ２０，２１−ジノルエブルナメニンの新規の誘導体、それらの製造方法及び得られる新規の中間体、それらの薬剤としての使用並びにそれらを含有する組成物
CA1161857A (en) 3-amino-1-benzoxepin derivatives, their salts and pharmaceutical compositions thereof and process for their preparation
US5314895A (en) Benzopyran class III antiarrhythmic agents
US4110472A (en) Derivatives of 1-(disubstituted phenoxy)-3-amino-2-hydroxypropanes
US4410548A (en) Propanolamine derivatives
FI76786B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-(3-trifluormetylfenyl)-1,2,3,6- tetrahydropyridiner.
US4626542A (en) 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds, pharmaceutical compositions and methods
WO1992001686A1 (en) 1,4-disubstituted piperazines
US4707499A (en) 3-alkyl-5-(substituted amino)methyl)dihydro-3-phenyl-2(3H)-furanones and imino analogs thereof used for treatment of arrhythmia
IE43413B1 (en) Heterocyclic compounds
US3496173A (en) 10-tertiaryaminoalkoxydibenzo(a,d)cycloheptadiene or salts thereof

Legal Events

Date Code Title Description
SPCF Request for grant of supplementary protection certificate

Free format text: SPC 17/95, 19951106

SPCG Supplementary protection certificate granted

Free format text: SPC 17/95 EXPIRES:20020103

MK9A Patent expired